Baseline patient characteristics, details of imatinib therapy and response
| Characteristic . | Data available . | Result . |
|---|---|---|
| Median age at diagnosis, range | 26 | 50 (0.9-78) years |
| Male, % | 26 | 21/26 (81%) |
| Median white cell count at diagnosis, range, ×109/L | 23 | 51 (4-138) |
| Median eosinophils at diagnosis, range, ×109/L | 21 | 3.5 (0.7-12) |
| Median platelets at diagnosis, range | 24 | 119 (60-506) |
| Cytogenetics at diagnosis | 26 | |
| t(5;12)(q33;p13) | 14 (54%) | |
| t(5;12) no further details available | 4 (12%) | |
| t(5;12)(q23;p23) | 2 (8%) | |
| t(5;12)(q33;p12.2) | 1 (4%) | |
| ins (2;12)(p21;q?13q?22),del(5)(q33q35) | 1 (4%) | |
| t(5;17)(q33;p13.3) | 1 (4%) | |
| t(1;5)(q23;q35) | 1 (4%) | |
| t(4;5)(q21;q33) | 1 (4%) | |
| t(2;5)(p21;q33) | 1 (4%) | |
| Fusion partners of PDGFRB | 26 | |
| ETV6 | 18 (69%) | |
| WDR48 | 1 (4%) | |
| PDE4DIP | 1 (4%) | |
| RAB5EP | 1 (4%) | |
| PRKG2 | 1 (4%) | |
| SPTBN1 | 1 (4%) | |
| BIN2 | 1 (4%) | |
| TP53BP1-PDGFRB | 1 (4%) | |
| Partner unknown | 1 (4%) | |
| Number of prior lines of therapy | 24 | |
| 0 | 8 (33%) | |
| 1 | 8 (33%) | |
| 2+ | 8 (33%) | |
| Median time from diagnosis to imatinib, range | 23 | 8.6 (0–123) months |
| Starting imatinib dose, milligrams daily | 26 | |
| 100 | 3 (12%) | |
| 300 | 1 (4%) | |
| 400 | 22 (84%) | |
| Best response to imatinib | 25 | |
| Stable disease | 1 (4%) | |
| HR | 1 (4%) | |
| Partial cytogenetic response | 1 (4%) | |
| CCR | 13 (52%) | |
| MolR | 9 (36%) | |
| Disease status at time of reporting | 25 | |
| Dead | 2 (8%) | |
| Stable disease | 1 (4%) | |
| HR | 0 (0%) | |
| Partial cytogenetic response | 1 (4%) | |
| CCR | 12 (40%) | |
| MolR | 9 (36%) | |
| Time to HR after imatinib | 22 | 1 (0.5–4*) months |
| Time best response after imatinib | 17 | 5 (1.5–36) months |
| Characteristic . | Data available . | Result . |
|---|---|---|
| Median age at diagnosis, range | 26 | 50 (0.9-78) years |
| Male, % | 26 | 21/26 (81%) |
| Median white cell count at diagnosis, range, ×109/L | 23 | 51 (4-138) |
| Median eosinophils at diagnosis, range, ×109/L | 21 | 3.5 (0.7-12) |
| Median platelets at diagnosis, range | 24 | 119 (60-506) |
| Cytogenetics at diagnosis | 26 | |
| t(5;12)(q33;p13) | 14 (54%) | |
| t(5;12) no further details available | 4 (12%) | |
| t(5;12)(q23;p23) | 2 (8%) | |
| t(5;12)(q33;p12.2) | 1 (4%) | |
| ins (2;12)(p21;q?13q?22),del(5)(q33q35) | 1 (4%) | |
| t(5;17)(q33;p13.3) | 1 (4%) | |
| t(1;5)(q23;q35) | 1 (4%) | |
| t(4;5)(q21;q33) | 1 (4%) | |
| t(2;5)(p21;q33) | 1 (4%) | |
| Fusion partners of PDGFRB | 26 | |
| ETV6 | 18 (69%) | |
| WDR48 | 1 (4%) | |
| PDE4DIP | 1 (4%) | |
| RAB5EP | 1 (4%) | |
| PRKG2 | 1 (4%) | |
| SPTBN1 | 1 (4%) | |
| BIN2 | 1 (4%) | |
| TP53BP1-PDGFRB | 1 (4%) | |
| Partner unknown | 1 (4%) | |
| Number of prior lines of therapy | 24 | |
| 0 | 8 (33%) | |
| 1 | 8 (33%) | |
| 2+ | 8 (33%) | |
| Median time from diagnosis to imatinib, range | 23 | 8.6 (0–123) months |
| Starting imatinib dose, milligrams daily | 26 | |
| 100 | 3 (12%) | |
| 300 | 1 (4%) | |
| 400 | 22 (84%) | |
| Best response to imatinib | 25 | |
| Stable disease | 1 (4%) | |
| HR | 1 (4%) | |
| Partial cytogenetic response | 1 (4%) | |
| CCR | 13 (52%) | |
| MolR | 9 (36%) | |
| Disease status at time of reporting | 25 | |
| Dead | 2 (8%) | |
| Stable disease | 1 (4%) | |
| HR | 0 (0%) | |
| Partial cytogenetic response | 1 (4%) | |
| CCR | 12 (40%) | |
| MolR | 9 (36%) | |
| Time to HR after imatinib | 22 | 1 (0.5–4*) months |
| Time best response after imatinib | 17 | 5 (1.5–36) months |
The patient who took 4 months initiated treatment at 100 mg daily; all other patients achieved HR within 2 months.